Seeking Funds For Phase III Antibiotic, Paratek Files For IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.